Paromomycin - PharmaKB

Paromomycin

Paromomycin (paromomycin) is a small molecule pharmaceutical. Paromomycin was first approved as Humatin on 1982-01-01. It is used to treat amebiasis, cryptosporidiosis, and protozoan infections in the USA.

Download report

Favorite

Events Timeline

Commercial

Clinical

Drug

Target

Variants

Financial

Trends

Safety

Events Timeline

YTD

Max

Events

FDA approval date

EMA approval date

Patent expiration date

Study first post date

Last update post date

Start date

Primary completion date

Completion date

Results first post date

Mock data
Subscribe for the real data

Commercial

Therapeutic Areas

Therapeutic Area	MeSH
infections	D007239
digestive system diseases	D004066
animal diseases	D000820

Trade Name

FDA

EMA

Paromomycin (discontinued: Humatin, Paromomycin)

Drug Products

FDA

EMA

New Drug Application (NDA)

Abbreviated New Drug Application (ANDA)

No data

Labels

FDA

EMA

Brand Name	Status	Last Update
care science essential first aid	C200263	2024-08-29
care science osha first aid	C200263	2024-02-05
emergency preparedness	OTC monograph final	2010-06-02
good neighbor pharmacy emergency preparedness and first aid contains 167 pieces	OTC monograph final	2010-06-11
humatin	ANDA	2023-01-10
madecassol	unapproved drug other	2019-10-08
paromomycin sulfate	ANDA	2017-11-07

Indications

FDA

EMA

Indication	Ontology	MeSH	ICD-10
cryptosporidiosis	—	D003457	A07.2
protozoan infections	—	D011528	B50-B64
amebiasis	EFO_0007144	D000562	A06

Agency Specific

FDA

EMA

No data

Patent Expiration

No data

ATC Codes

A: Alimentary tract and metabolism drugs

— A07: Antidiarrheals, intestinal antiinflammatory/antiinfective agents

— A07A: Intestinal antiinfectives

— A07AA: Antibiotics, intestinal

— A07AA06: Paromomycin

HCPCS

No data

Clinical

Clinical Trials

1237 clinical trials

View more details

Mock data
Subscribe for the real data

Indications Phases 4

Indication	MeSH	Ontology	ICD-10	Ph 1	Ph 2	Ph 3	Ph 4	Other	Total
Mycobacterium avium-intracellulare infection	D015270	EFO_0007386	—	—	—	2	3	4	9
Pneumonia	D011014	EFO_0003106	J18	—	1	2	2	—	5
Sinusitis	D012852	EFO_0007486	J32	—	1	1	1	—	3
Tonsillitis	D014069	—	—	—	1	1	1	—	3
Lung diseases	D008171	EFO_0003818	J98.4	—	—	—	3	—	3
Mycobacterium avium complex	D015269	—	—	—	—	—	3	—	3
Rhinosinusitis	D000096825	—	—	—	—	—	1	—	1
Bacterial vaginosis	D016585	EFO_0003932	—	—	—	—	1	—	1
Vaginal diseases	D014623	—	—	—	—	—	1	—	1

Indications Phases 3

Indication	MeSH	Ontology	ICD-10	Ph 1	Ph 2	Ph 3	Ph 4	Other	Total
Hiv infections	D015658	EFO_0000764	B20	3	2	2	—	7	14
Malaria	D008288	EFO_0001068	B54	2	6	7	—	—	10
Infections	D007239	EFO_0000544	—	2	1	2	—	5	10
Communicable diseases	D003141	—	—	2	1	2	—	5	10
Falciparum malaria	D016778	EFO_0007444	B50	—	7	7	—	—	9
Mycobacterium infections	D009164	—	A31.9	—	—	2	—	4	6
Covid-19	D000086382	—	U07.1	—	—	2	—	—	2
Pharyngitis	D010612	—	R07.0	—	1	1	—	—	2
Otitis media	D010033	EFO_0004992	H66.9	—	1	1	—	—	2
Otitis	D010031	—	—	—	1	1	—	—	2

Show 12 more

Indications Phases 2

Indication	MeSH	Ontology	ICD-10	Ph 1	Ph 2	Ph 3	Ph 4	Other	Total
Acquired immunodeficiency syndrome	D000163	EFO_0000765	B20	1	1	—	—	2	4
Bacterial infections	D001424	—	A49	2	1	—	—	—	3
Pharmacokinetics	D010599	—	—	—	1	—	—	—	1
Chronic obstructive pulmonary disease	D029424	EFO_0000341	J44.9	—	1	—	—	—	1
Obstructive lung diseases	D008173	—	—	—	1	—	—	—	1
Tracheostomy	D014139	—	—	—	1	—	—	—	1
Fibrosis	D005355	—	—	—	1	—	—	—	1
Cystic fibrosis	D003550	EFO_0000390	E84	—	1	—	—	—	1
Pneumocystis pneumonia	D011020	EFO_0007448	B59	—	1	—	—	—	1
Bcr-abl positive chronic myelogenous leukemia	D015464	EFO_0000340	—	1	1	—	—	—	1

Show 4 more

Indications Phases 1

Indication	MeSH	Ontology	ICD-10	Ph 1	Ph 2	Ph 3	Ph 4	Other	Total
Healthy volunteers/patients	—	—	—	2	—	—	—	—	2
Toxoplasmosis	D014123	EFO_0007517	B58	1	—	—	—	—	1
Cerebral toxoplasmosis	D016781	EFO_0007200	B58.2	1	—	—	—	—	1
Encephalitis	D004660	—	—	1	—	—	—	—	1

Indications Without Phase

Indication	MeSH	Ontology	ICD-10	Ph 1	Ph 2	Ph 3	Ph 4	Other	Total
Cryptosporidiosis	D003457	—	A07.2	—	—	—	—	2	2
Immunologic deficiency syndromes	D007153	—	D84.9	—	—	—	—	2	2
Respiratory tract infections	D012141	—	J06.9	—	—	—	—	1	1
Bronchiolitis obliterans	D001989	EFO_0007183	J44.81	—	—	—	—	1	1
Bone marrow transplantation	D016026	—	—	—	—	—	—	1	1
Bronchiolitis	D001988	—	—	—	—	—	—	1	1
Bronchiolitis obliterans syndrome	D000092122	—	D89.811	—	—	—	—	1	1
Tuberculosis	D014376	EFO_0000774	A15-A19	—	—	—	—	1	1

Epidemiology

Epidemiological information for investigational and approved indications

View more details

Drug

General

Drug common name	Paromomycin
INN	paromomycin
Description	Paromomycin sulfate is an aminoglycoside sulfate salt resulting from the treatment of paromomycin with sulfuric acid. A broad-spectrum antibiotic, it is used for the treatment of acute and chronic intestinal protozoal infections, but is not effective for extraintestinal protozoal infections. It is also used as a therapeutic against visceral leishmaniasis. It has a role as an antibacterial drug, an antiprotozoal drug, an anthelminthic drug and an antiparasitic agent. It is functionally related to a paromomycin.
Classification	Small molecule
Drug class	antibiotics (Streptomyces strain)
Image (chem structure or protein)
Structure (InChI/SMILES or Protein Sequence)	NC[C@@H]1O[C@H](O[C@@H]2[C@@H](CO)O[C@@H](O[C@@H]3[C@@H](O)[C@H](N)C[C@H](N)[C@H]3O[C@H]3O[C@H](CO)[C@@H](O)[C@H](O)[C@H]3N)[C@@H]2O)[C@H](N)[C@@H](O)[C@@H]1O